A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus
Conclusion: CVC showed efficacy and favorable safety in treatment-naive HIV-1-infected study participants, supporting selection of CVC200 for phase 3 studies.
Trial registration: NCT01338883.
Source: AIDS - Category: Infectious Diseases Tags: Clinical Science Source Type: research
More News: Atripla | Cholesterol | HIV AIDS | Infectious Diseases | Science | Study | Truvada | Viread | Virology